To learn more about this report, download the PDF brochure The dual burden of type 2 diabetes and obesity drives the demand for GLP-1 analogues A key factor driving the demand for GLP-1 analogues is the surge in the number of people with type 2 diabetes and obesity due to growing adoption of sedentary lifestyles, poor food choices, and rapid urbanization
1384/18), the Israel Science Foundation-Broad Institute Joint Program (grant No
In addition to taking these GLP-1 pills, I have been making sure to have extra fiber in my diet and have been more physically active than I have been in a while
Since the discovery and functional verification of GLP-1 in the 1980s ( However, the therapeutic utility of native GLP-1 was limited by its rapid enzymatic degradation and short plasma half-life, which prompted the development of longer-acting receptor agonists
Until then, patients should focus on safe, available, evidence-based care